Meaning of elevated CA 19-9 serum levels in chronic hepatitis and HCV-related cirrhosis

Minerva Gastroenterologica e Dietologica

Volumn 53, Issue 4, 2007, Pages 305-309

  Bertino, G ^a   Ardiri, A M ^a   Boemi, P ^a   Bruno, C M ^a   Valenti, M ^a   Mazzarino, M C ^a   Consolo, M ^a   Calvagno, G S ^a   Pulvirenti, D ^b   Neri, S ^b  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

CA 19 9 antigen; Hepatitis C; Liver cirrhosis

Indexed keywords

CA 19-9 ANTIGEN;

ADULT; AGED; ARTICLE; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; JAUNDICE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PANCREAS TUMOR; STATISTICAL ANALYSIS;

ADULT; AGED; CA-19-9 ANTIGEN; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RADIOGRAPHY, ABDOMINAL; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED;

EID: 38649102457     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Motoo Y, Satomura Y, Mouri I, Mouri H, Ohtsubo K, Sakai J et al. Serum levels of pancreatitis-associated protein in digestive diseases with special reference to gastrointestinal cancers. Dig Dis Sci 1999;44:1142-7.
2. Plemenos MF, Dimas C, Kotsios A, Gennatas K, Pafiti AK. Prognostic significance of the immunohistochemical localization and serological detection of CA19-9 tumor antigen in colon carcinoma. J BUON 2004;9:73-6.
3. Markocka-Maczka K. Ca 19-9 antigen in differentiation of pancreatic inflammatory and neoplastic tumors. Wiad Lek 2003;56:537-40.
4. Ducreux M, Boige V, Malka D. CA 19-9 and pancreatic carcinoma, a revival? Onkologie 2007;30:12-3.
5. Nouts A, Levy P, Voitot H, Bernades P. Diagnostic value of serum Ca 19-9 antigen in chronic pancreatitis and pancreatic adenocarcinoma Gastroenterol Clin Biol 1998;22:152-9.
6. Tanaka N, Okada S, Ueno H, Okusaka T, Ikeda M. The usefulness of serial changes in serum CA19-9 levels in the diagnosis of pancreatic cancer. Pancreas 2000;20:378-81.
7. Nowak J, Jakubowska D, Wiczkowski A, Sprzaczkowska K, Stechly T, Zmudzinski W et al. Carbohydrate antigens CA 19-9, CA 242, CA 50 in liver diseases. Wiad Lek 1998;51:484-91.
8. Park KH, Kim JS, Lee JH, Kim HJ, Kim JY, Yeon JE et al. Significances of serum level and immunohistochemical stain of CA19-9 in simple hepatic cysts and intrahepatic biliary cystic neoplasms. Korean J Gastroenterol 2006;47:52-8.
9. Vandemergel X, Vandergheynst F, Decaux G. Very high elevation of CA19-9 level in a patient with steatosis. Acta Gastroenterol Belg 2005;68:380-1.
10. Montalto M, Santoro L, Vastola M, Curigliano V, Ricci R, Vecchio FM et al. Normalisation of high CA 19-9 values in autoimmune hepatitis after steroidal treatment. Int J Immunopathol Pharmacol 2005;18:603-7.
11. de Goede E, Yap SH. An exceptional high concentra-tion of serum CA 19.9 in a patient with alcoholic liver disease. Gut 1997;41:579-80.
12. Giannini E, Borro P, Botta F, Chiarbonello B, Fasoli A, Malfatti F et al. Cholestasis is the main determinant of abnormal CA 19-9 levels in patients with liver cirrhosis. Int J Biol Markers 2000;15:226-30.
13. Maestranzi S, Przemioslo R, Mitchell H, Sherwood RA. The effect of benign and malignant liver diseases on the tumor markers CA19-9 and CEA Ann Clin Biochem 1998;35:99-103.
14. Schoniger-Hekele M, Muller C. The combined elevation of tumor markers CA 19-9 and CA 125 in liver disease patients is highly specific for severe liver fibrosis. Dig Dis Sci 2006;51:338 45.
15. Giannini E, Risso D, Botta F, Chiarbonello B, Fasoli A, Malfatti F et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med 2003;163:218-24.
16. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-26.
17. Le Calvez S, Thabut D, Messous D, Munteanu M, Ratziu V, Imbert-Bismout F et al. The predictive value of fibrotest vs.APRI for the diagnosis of fibrosis in chronic hepatitis C. Hepatology 2004;39:862-3.
18. Lackener C, Struber G, Liegl B, Leibl S, Ofner P, Bankuti C et al. Comparison and validation for simpler non invasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 2005;41:1376-82.
19. Sebastianini G, Vario A, Guido M, Noventa F, Plebani M, Pistis R et al. Stepwine combination algorithms of non-invasive marker to diagnose significant fibrosis in chronic hepatitis C. J Hepatol 2006;44:686-93.
20. Chrysanthos NV, Papatheodoridis GV, Savvas S, Kafiri G, Petraki K, Manesis EK et al. Aspartate aminotransferase to platelet ratio index fibrosis evaluation in chronic viral hepatitis. Eur J Gastroenterol Hepatol 2006;18:389-96.
21. Snyder N, Gajula L, Xiao SY, Grady J, Luxon B, Lau DT et al. APRI: an easy and validated predictor of hepatic fibrosis in chronic hepatitis C. J Clin Gastroenterol. 2006;40:535-42.
22. Snyder N, Gajula L, Xiao SY, Grady J, Luxon B, Lau DT et al. The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C. Clin Chim Acta 2007;40:461-3.
23. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinton L, Martinez-Bauer E et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002;36:986-92.
24. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T et al. MULTIVIRC Group. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;353:1069-75.
25. Ngo Y, Munteanu M, Messous D, Charlotte F, Imbert-Bismut F, Thabut D et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 2006;52:1887-96.
26. Gebo KA, Herlong HF, Torbenson MS, Jenckes MW, Chander G, Ghanem KG et al. Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology 2002;36(Suppl 1):S162-71
27. Halfon P, Bourliere M, Deydier R, Botta-Fridlund D, Renou C, Tran A et al. Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. Am J Gastroenterol 2006;101:547-55.
28. Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J et al. GERMED cyt04 group. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat 2002;9:128-33.
29. Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005;51:1867-73.
30. Bourliere M, Penaranda G, Renou C, Botta-Fridlund D, Tran A, Portal I et al. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies. J Viral Hepat 2006;13:659-70.